the market?
Celgene
NASDAQ: CELG
123.44
-0.06
(-0.05%)
| Today's Open | $124.11 |
|---|---|
| Previous Close | $123.50 |
| Daily Range | $122.56 - $128.35 |
| 52-Week Range | $58.53 - $131.82 |
| Market Cap | $51.5B |
| P/E Ratio | 37.54 |
| Dividend (Yield) | $0.00 (0.0%) |
| Volume | 4,199,827 |
| Average Daily Volume | 3,331,854 |
| Current FY EPS | $5.21 |
How do you think CELG
will perform against the market?
Top CELG Bull/Bear Pitches
Jeffreyw (< 20)
Submitted
October 25, 2010
Big investment in discovery and production of new therapies. Monitizing these treatments will take time, but could be huge.
NetscribeBiotech (< 20)
Submitted
February 22, 2007
Celgene is a biopharmaceutical company focused on novel therapies to treat a broad range of hematopoietic, immunological, neuronal, and cancerous conditions. Celgene currently markets Thalomid for EN … More
News & Commentary
3 Companies That Put the "Tech" in "Biotech"
From 3-D modeling to tamper-resistant drugs to personalized genomics, these companies put the "tech" in "biotech."3 Earnings Reports That Caught My Attention Last Week
Investors may have ignored these earnings reports, but I certainly did not!After Hours Most Active for May 10, 2013 : HAL, BAC, GM, SINA, QQQ, LYB, PCG, SYMC, DDD, CELG, INTC
After Hours Most Active for May 10, 2013 : HAL, BAC, GM, SINA, QQQ, LYB, PCG, SYMC, DDD, CELG, INTC, ICONMinyanville's T3 Morning Market Call: Time to Take Profits or Stay the Course?
Banks have been a bit lethargic while tech continues to be filled with opportunity.Sector
Healthcare
Industry
Drugs
Celgene (CELG) Description
A biopharmaceutical company primarily engaged in the discovery, development and commercialization of innovative therapies designed to treat cancer and immune-inflammatory related diseases. Website: http://www.celgene.com/
CEO Rating by Glassdoor
More details for Celgene Jobs
Celgene reviews from employees
